Abstract:Nanomedicine, under the spotlight of biomedical research, has embraced rapid evolution and considerable accomplishments in the fundamental discovery and drug development for potential clinical translation. For the past decades, many novel concepts have been proposed by using engineered nanoparticles or nanomaterials for drug delivery, disease prevention, intervention and monitoring. Given the unique physicochemical properties, nanoparticles protect the payload (therapeutic or imaging agents, nucleic acids, etc.) from degradation, fine-tune the in vivo transport for targeting and clearance, modulate the controllable payload release. 1 From the very first FDAapproved nano-drug in 1995 -Doxil (in the form of PEGylated liposomal doxorubicin) 2 to now broadly applied lipid nanoparticle-based Covid-19 mRNA vaccines (under emergency use authorization in 2020), 3,4 nanomedicines have not only improved the life quality of patients bearing cancers, rare genetic disorders 5 and other diseases, but also protected healthy people effectively from viral infection and resulting complications. Over a hundred other candidates are being investigated in clinical trials as nanoparticle vaccines, therapies and diagnostics. 6 Meanwhile, the overall success rate falls short in the clinical translation of nanomedicines. And the clinically approved nanomedicines are mostly in the context of liposomes or lipid-based nanocarriers. In many research studies, the strategies in nanomedicine design, material synthesis and analytics often lack the consideration of translation potential or clinically relevant solutions. 7 Notably, the practice of transforming an interesting concept into a scalable, applicable and marketable medical product is quite challenging, as its development may be hampered or terminated at any time due to the limitations towards preclinical proof of concept, chemistry, manufacturing and controls (CMC), clinical safety and efficacy, regulatory compliance and even post-approval. So, nanomedicine researchers have recently concluded a series of developmental barriers to overcome, 8 including the formulation, toxicological, physiological, immunological, and translational barriers. More importantly, the successful clinical translation involves extensive collaborations with pharmaceutical, clinical and regulatory groups in the assessment of drug's critical quality attributes, pharmacokinetics, dosimetry, therapeutic index, cost-effectiveness as well as consideration of the complexity of a disease.We opened the Research Topic on Nanomedicine Development and Clinical Translation last year, aiming to better bridge the basic science research and clinical translation for current nanomedicine development. Herein, our hope is to receive the input from innovative researchers pinpointing the underlying challenges and opportunities of nanomedicine, so that clinical translation of nano-products may be accelerated become successful broadly.

Current state of nanomedicine drug products: An industry perspective

Progress, challenges, and future of nanomedicine

Editorial: Nanomedicine development and clinical translation

Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics

Evolution of nanomedicine formulations for targeted delivery and controlled release

Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives

Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”

Challenges and Opportunities of Nanomedicines in Clinical Translation

An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success

Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions

Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.

The Role of Artificial Intelligence and Machine Learning in Accelerating the Discovery and Development of Nanomedicine

Re-envisioning the design of nanomedicines: harnessing automation and artificial intelligence

A Journey of Challenges And Victories: The Worldview of Nanomedicine from 2000 to 2023

Material Trends and Clinical Costings in Systematically Identified CDER‐Approved Nanomedicines

Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems

Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy

Diverse Applications of Nanomedicine

Current approaches of nanomedicines in the market and various stage of clinical translation

Nanomaterial-enabled drug transport systems: a comprehensive exploration of current developments and future avenues in therapeutic delivery

Unlocking the potential of nanocarrier-mediated mRNA delivery across diverse biomedical frontiers: A comprehensive review